Neurocrine Biosciences: Keswani proposes $8.97M sale

The four acquisition entries are 802, 802, 37,828 and 14,182 shares, each from an exercise of options under a registered plan for cash on November 10, 2026.

Available on EDGAR 11/10/2026 - 04:48 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:47 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Neurocrine Biosciences Inc. (NBIX) is the issuer named in Sanjay Keswani’s notice of a proposed sale of 53,614 common shares. Keswani, identified as a former affiliate and signing as Sanjay Chandru Keswani, lists an aggregate market value of $8,973,487.77 and an approximate sale date of November 10, 2026.

Key Figures

Shares to be sold: 53,614 common shares Aggregate market value: $8,973,487.77 Shares outstanding: 101,218,643 common shares

3 metrics

Shares to be sold 53,614 common shares Proposed sale; approximate sale date November 10, 2026

Aggregate market value $8,973,487.77 Securities listed for the proposed sale

Shares outstanding 101,218,643 common shares Common shares outstanding listed in the securities information

Key Terms

Aggregate Market Value, Exercise of Options Under a Registered Plan, Former Affiliate

3 terms

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Options Under a Registered Plan financial

"Exercise of Options Under a Registered Plan"

Former Affiliate regulatory

"Relationship to Issuer: Former Affiliate"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares does Sanjay Keswani propose to sell?

Sanjay Keswani, identified as a former affiliate, proposes to sell 53,614 common shares with an aggregate market value of $8,973,487.77; the approximate sale date is November 10, 2026.

How did Sanjay Keswani acquire the NBIX shares listed for sale?

The four acquisition entries list 802, 802, 37,828 and 14,182 shares, each acquired through an exercise of options under a registered plan for cash on November 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001818524
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEUROCRINE BIOSCIENCES, INC.
SEC File Number	000-22705
Address of Issuer	6027 Edgewood Bend Court San Diego CALIFORNIA 92130
Phone	(858) 617-7600
Name of Person for Whose Account the Securities are To Be Sold	SANJAY KESWANI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	53614	8973487.77	101218643	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Exercise of Options Under a Registered Plan	Issuer			802	11/10/2026	Cash
Common	11/10/2026	Exercise of Options Under a Registered Plan	Issuer			802	11/10/2026	Cash
Common	11/10/2026	Exercise of Options Under a Registered Plan	Issuer			37828	11/10/2026	Cash
Common	11/10/2026	Exercise of Options Under a Registered Plan	Issuer			14182	11/10/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sanjay Chandru Keswani
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)